212 related articles for article (PubMed ID: 36914722)
1. The emerging role of PI3K inhibitors for solid tumour treatment and beyond.
Belli C; Repetto M; Anand S; Porta C; Subbiah V; Curigliano G
Br J Cancer; 2023 Jun; 128(12):2150-2162. PubMed ID: 36914722
[TBL] [Abstract][Full Text] [Related]
2. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
3. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
4. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
VanLandingham NK; Nazarenko A; Grandis JR; Johnson DE
Adv Biol Regul; 2023 Jan; 87():100934. PubMed ID: 36402737
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
6. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the safety and efficacy of currently used treatment modalities in the treatment of patients with PIK3CA-related overgrowth spectrum.
Bernhard SM; Adam L; Atef H; Häberli D; Bramer WM; Minder B; Döring Y; Laine JE; Muka T; Rössler J; Baumgartner I
J Vasc Surg Venous Lymphat Disord; 2022 Mar; 10(2):527-538.e2. PubMed ID: 34358672
[TBL] [Abstract][Full Text] [Related]
8. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA-related overgrowth: silver bullets from the cancer arsenal?
Madsen RR; Semple RK
Trends Mol Med; 2022 Apr; 28(4):255-257. PubMed ID: 35272946
[TBL] [Abstract][Full Text] [Related]
10. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
11. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Schwartzberg LS; Vidal GA
Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Fiascarelli A; Merlino G; Capano S; Talucci S; Bisignano D; Bressan A; Bellarosa D; Carrisi C; Paoli A; Bigioni M; Tunici P; Irrissuto C; Salerno M; Arribas J; de Stanchina E; Scaltriti M; Binaschi M
Breast Cancer Res Treat; 2023 May; 199(1):13-23. PubMed ID: 36913051
[TBL] [Abstract][Full Text] [Related]
13. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Madsen RR; Vanhaesebroeck B; Semple RK
Trends Mol Med; 2018 Oct; 24(10):856-870. PubMed ID: 30197175
[TBL] [Abstract][Full Text] [Related]
15. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
16. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
17. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
[No Abstract] [Full Text] [Related]
19. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Wang J; Kuropatwinski K; Hauser J; Rossi MR; Zhou Y; Conway A; Kan JL; Gibson NW; Willson JK; Cowell JK; Brattain MG
Mol Cancer Ther; 2007 Mar; 6(3):1143-50. PubMed ID: 17363507
[TBL] [Abstract][Full Text] [Related]
20. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]